Viatris Inc VTRS

Morningstar Rating
$17.35 +0.05 (0.29%)
View Full Chart

Company Report

Viatris Looks to New Launches and Cost Savings for Long-Term Growth

Viatris is one of the largest generic drug manufacturers in the world. Generic drugs make up about 35% of the company's sales. Generics continue to suffer annual low- to mid-single-digit erosion in developed markets like North America and the majority of Europe. Because price and margin headwinds are predominantly in small-molecule oral tablets that are easy to produce, we expect Viatris’ pipeline to focus more on complex generics—drugs with complex formulations, dosage forms, or that are injected or have more complex administration.

Price vs Fair Value

VTRS is trading at a LOCK|mmL>fB premium.
Price
$17.30
Fair Value
LOCK|.ZJ
Uncertainty
LOCK|!t H#?S
1-Star Price
LOCK|.LMg
5-Star Price
LOCK|T!S
Economic Moat
LOCK|f@
Capital Allocation
LOCK|J$T^$<m

Bulls Say, Bears Say

Bulls

Recent additions to the pipeline, which span many attractive therapeutic areas, should support Viatris' long-term growth potential and margin expansion.

Bears

Base business erosion will persist in developed markets and act as a headwind that Viatris must try to offset with new product launches.

News

Trading Information

Previous Close Price
$17.29
Day Range
$17.3517.51
52-Week Range
$8.6317.67
Bid/Ask
$17.33 / $17.35
Shares Outstanding
1.16B
Market Cap
$20.36B
Volume/Avg
304,203 / 11M

Key Statistics

Price/Earnings (Normalized)
7.06
Price/Sales
1.38
Dividend Yield (Trailing)
2.78%
Dividend Yield (Forward)
2.78%
Total Yield
4.38%

Company Profile

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Mid Value
Total Number of Employees
30,000

Competitors

Valuation

Metric
VTRS
RDY
TEVA
Price/Earnings (Normalized)
7.0622.2510.93
Price/Book Value
1.372.644.53
Price/Sales
1.382.762.16
Price/Cash Flow
6.0514.5112.47
Price/Earnings
VTRS
RDY
TEVA

Financial Strength

Metric
VTRS
RDY
TEVA
Quick Ratio
0.901.260.53
Current Ratio
1.601.801.01
Interest Coverage
−0.7114.672.51
Quick Ratio
VTRS
RDY
TEVA

Profitability

Metric
VTRS
RDY
TEVA
Return on Assets (Normalized)
7.58%9.02%8.61%
Return on Equity (Normalized)
18.88%13.64%47.02%
Return on Invested Capital (Normalized)
10.87%11.54%16.91%
Return on Assets
VTRS
RDY
TEVA

Drug Manufacturers - Specialty & Generic Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Merck KGaA ADR
MKKGY
LOCK|p@yzn$$LOCK|T!Vq$68B
Haleon PLC ADR
HLN
LOCK|mZgH#qLOCK|r&$44B
Teva Pharmaceutical Industries Ltd ADR
TEVA
LOCK|@VM@>w^LOCK|Hvfv@$38B
Zoetis Inc Class A
ZTS
LOCK|!j?r<tvsLOCK|%c$32B
Elanco Animal Health Inc
ELAN
LOCK|>#LOCK|wm$$13B
Dr Reddy's Laboratories Ltd ADR
RDY
LOCK|ND$Ct?pLOCK|Dq$10B
Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
LOCK|F$?R@NLOCK|S#<$8B
Prestige Consumer Healthcare Inc
PBH
LOCK|#Xb^FXLOCK|P^%>$2B
Perrigo Co PLC
PRGO
LOCK|t<XtNjLOCK|DD%$1B

Sponsor Center